Abstract
The great progress of knowledge of both M. tuberculosis physiology and how human host and bacilli interact has provided fertile ground for improving diagnosis and cure of TB infection. Once M. tuberculosis has infected humans, it elaborates strategies for evading the risk to killing by the cells of the host immune system and by the anti-tuberculosis (anti-TB) agents employed to cure infection. These strategies give rise to a bacterial multidrug resistance (MDR) status. This stems firstly from genetic mutations targeting a constellation of drug-processing mechanisms that still need full identification, as drug efflux pumps and drug activating/ inactivating enzymes (genetic resistance). Secondly, from the bacterial adaptation to stressful environmental conditions by adopting a temporary dormancy state lasting for decades and characterized by indifference to anti-TB drugs (phenotypic resistance or tolerance). The clarification of the strategies elaborated for surviving by M. tuberculosis has brought to the identification in the last few years of a number of mycobacterial molecular targets worth to exploitation for the development of novel and powerful anti-TB drugs. These targets include drug-efflux pump systems, considered partly responsible for genetic multi-drug resistance, and several enzymes and pump systems, as well, that sustain the metabolic adaptations of M. tuberculosis in the host and give rise to its phenotypic drug resistance.
Keywords: Genetic/phenotypic resistance, toxin/antitoxin module, DosR regulon, drug efflux pump, bacterial persistence, metabolic adaptations.
Current Medicinal Chemistry
Title:Human Tuberculosis II. M. tuberculosis Mechanisms of Genetic and Phenotypic Resistance to Anti-Tuberculosis Drugs
Volume: 23 Issue: 12
Author(s): Giampietro Sgaragli and Maria Frosini
Affiliation:
Keywords: Genetic/phenotypic resistance, toxin/antitoxin module, DosR regulon, drug efflux pump, bacterial persistence, metabolic adaptations.
Abstract: The great progress of knowledge of both M. tuberculosis physiology and how human host and bacilli interact has provided fertile ground for improving diagnosis and cure of TB infection. Once M. tuberculosis has infected humans, it elaborates strategies for evading the risk to killing by the cells of the host immune system and by the anti-tuberculosis (anti-TB) agents employed to cure infection. These strategies give rise to a bacterial multidrug resistance (MDR) status. This stems firstly from genetic mutations targeting a constellation of drug-processing mechanisms that still need full identification, as drug efflux pumps and drug activating/ inactivating enzymes (genetic resistance). Secondly, from the bacterial adaptation to stressful environmental conditions by adopting a temporary dormancy state lasting for decades and characterized by indifference to anti-TB drugs (phenotypic resistance or tolerance). The clarification of the strategies elaborated for surviving by M. tuberculosis has brought to the identification in the last few years of a number of mycobacterial molecular targets worth to exploitation for the development of novel and powerful anti-TB drugs. These targets include drug-efflux pump systems, considered partly responsible for genetic multi-drug resistance, and several enzymes and pump systems, as well, that sustain the metabolic adaptations of M. tuberculosis in the host and give rise to its phenotypic drug resistance.
Export Options
About this article
Cite this article as:
Sgaragli Giampietro and Frosini Maria, Human Tuberculosis II. M. tuberculosis Mechanisms of Genetic and Phenotypic Resistance to Anti-Tuberculosis Drugs, Current Medicinal Chemistry 2016; 23 (12) . https://dx.doi.org/10.2174/0929867323666160405112820
DOI https://dx.doi.org/10.2174/0929867323666160405112820 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Solanum pubescens</i> Wild Fruits Essential Oil - A Golden Casket for its
Antimicrobial and Anti-inflammatory Mediated Wound Healing Efficacy
in Vertebrate Model <i>Mus musculus</i>
Current Topics in Medicinal Chemistry Synthesis, <i>In silico</i> and <i>In vitro</i> Analysis of Hydrazones as Potential Antituberculosis Agents
Current Computer-Aided Drug Design Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents
Infectious Disorders - Drug Targets Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs
Current Pharmaceutical Design Identification of Thiazoloquin(az)olin(on)es Derivatives as CD38 Inhibitors Through 3D-QSAR and Molecular Docking Simulations
Letters in Drug Design & Discovery The Role of Machine Learning in Centralized Authorization Process of Nanomedicines in European Union
Current Topics in Medicinal Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Prospects of Applying Enhanced Semi-Empirical QM Methods for 2101 Virtual Drug Design
Current Medicinal Chemistry Review of Current Chemoinformatic Tools for Modeling Important Aspects of CYPsmediated Drug Metabolism. Integrating Metabolism Data with Other Biological Profiles to Enhance Drug Discovery
Current Drug Metabolism Shikimate Kinase: A Potential Target for Development of Novel Antitubercular Agents
Current Drug Targets An Efficient Immobilization of Cholesterol Oxidase from Bacillus sp. COX-T<sub>3</sub> onto Psyllium Husk Fibers
Current Biotechnology Recent Advances in the Rational Drug Design Based on Multi-target Ligands
Current Medicinal Chemistry Using QM/MM Methods for the Exploration of Electron Transfer Pathways
Current Inorganic Chemistry (Discontinued) In silico Analysis of Several Signal Peptides for the Excretory Production of Reteplase in Escherichia coli
Current Proteomics Recent Advances in the Chemistry of Phthalimide Analogues and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design Increased [11C]Choline Uptake in Bronchioloalveolar Cell Carcinoma with Negative [18F]FDG Uptake. A PET/CT and Pathology Study
Current Radiopharmaceuticals Type II NADH:Menaquinone Oxidoreductase of Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Quickness of HIV and Tuberculosis Diagnostic Procedures in Prison of Tehran, Iran
Infectious Disorders - Drug Targets